STUDIO

Cyxone updates on study results

BioStock Studio: Cyxone comments on the Covid-19 study result

Biotech company Cyxone has announced results from their phase II trial with drug candidate Rabeximod in patients with moderate to severe Covid-19. The data...

RECOMMENDED READING

Respiratorius

Respiratorius gets green light for PK study

Respiratorius is ready to initiate a pharmacokinetic phase I study with VAL001. The aim...
Key steps taken by BiBBInstruments in 2021

Key steps taken by BiBBInstruments in 2021

Despite some turbulence for BiBBInstruments in the early parts of 2021, the Swedish medtech...

EVENT